Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07775924 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT07775924 · ClinicalTrials.gov record · last posted 2026-08-27

A Study to Assess the Efficacy and Safety of GIA632 Across a Range of Doses in Participants With Moderate to Severe Cutaneous Lichen Planus

Name: A Study to Assess the Efficacy and Safety of GIA632 Across a Range of Doses in Participants With Moderate to Severe Cutaneous Lichen Planus — clinical trial record (NCT07775924)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: ELIPSI

StatusRecruiting

PhasePhase 2

SponsorNovartis Pharmaceuticals

Started2026-09-10

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This study will evaluate the safety and efficacy of GIA632 in participants with moderate to severe cutaneous lichen planus (cLP).

Protocol amendment history 1 change detected by DataLookout

2026-08-27

Recruitment opened

Trial Details

NCT Number	NCT07775924
Lead Sponsor	Novartis Pharmaceuticals
Conditions	Cutaneous Lichen Planus
Enrollment	259 participants
Start Date	2026-09-10
Primary Completion	2028-11-22 (estimated)
Study Completion	2030-02-13 (estimated)
Updated on ClinicalTrials.gov	2026-08-27